The extent of ischemia identified on stress cardiac magnetic resonance imaging (CMR) was a strong predictor of the composite ...

HeartFlow recently filed a Form S-1 with the SEC to confirm its intent to complete an initial public offering (IPO) and go ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Researchers develop an AI model that uses ECG data to predict the risk for adverse vascular events in patients with migraine.

Patients with abnormal findings had worse outcomes down the road. Still unknown is exactly how to modify that risk.

The former Emperor of Japan has been admitted to a hospital in Tokyo to undergo treatment for a heart condition, the Imperial ...

The global ECG Sensor Patches Market, valued at US$0.95 billion in 2024 stood at US$1.05 billion in 2025 and is projected to advance at a resilient ...

This marks the second FDA-cleared ECG-AI device in Tempus’ cardiovascular product suite, following its previously cleared Tempus ECG-AF solution. The new software analyzes resting, non-ambulatory ...

Dr. Gérald Kierzek, emergency physician, reveals the hidden nighttime signs and what they could mean for your health.

Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...

MyoBioScan: A non-invasive wearable patch for real-time cardiovascular monitoring, integrating ECG acquisition and sweat-based biomarker analysis.

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .